Article
Merck beats first-quarter expectations on Keytruda, Gardasil strength
Rating:
0.0
Views:
90
Likes:
1
Library:
1
Drugmaker Merck & Co Inc on Thursday posted better-than-expected results for the first quarter on the strength of its blockbuster cancer immunotherapy Keytruda and human papillomavirus (HPV) vaccine Gardasil.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value